Press Coverage of Bitter Pill Campaign

Coverage of SEC Decision Clearing 2018 Proposals for Proxy:

26th March 2018

SEC: Biogen can't block shareholder vote on drug prices, executive pay

Boston Business Journal

The U.S. Securities and Exchange Commission will allow investors in Cambridge-based Biogen and four other big pharmaceutical companies to pursue non-binding resolutions urging the firms to examine a possible link between rising drug costs and executive pay.

 

26th March 2018

Investors in AbbVie, Lilly, Amgen and more set to vote on executive pay, drug pricing

Fierce Pharma

Despite resistance from top pharma companies, shareholders are set to vote this spring on resolutions seeking more information about potential links between executive pay and rising drug prices.

Several drug industry players resisted the proxy vote, but the SEC ruled in favor of the Interfaith Center on Corporate Responsibility, which filed the resolutions last year. 

 

26th March 2018

SEC greenlights shareholder proposals for several big drug makers over pricing

STAT

The Securities and Exchange Commission agreed to allow shareholders in five large drug makers to vote on a proposal demanding the companies compile reports about the risks created by high prices and also examine the extent to which pricing strategies propel executive compensation. The companies involved are AbbVie (ABBV), Amgen (AMGN), Biogen (BIIB), Bristol-Myers Squibb (BMY), and Eli Lilly (LLY).

 

28th March 2018

Bristol-Myers CEO Giovanni Caforio nets $18.7M in 2017 pay, a 10% raise

FiercePharma 

BMS was among a handful of drugmakers to receive executive pay scrutiny from the Interfaith Center on Corporate Responsibility this year. The faith-based investor group has said pharma's executive pay focuses too much on short-term goals such as earnings and revenue, and not enough on R&D. It's requesting a report from BMS, AbbVie, Amgen, Biogen and Eli Lilly about how drug pricing risks are incorporated into executive pay decisions. 

 

30th March 2018

Do drug prices affect CEO pay? Faith-based investor group wants to know

Wall Street Journal - Market Watch

Faith-based investor group the Interfaith Center on Corporate Responsibility is pushing for drug-price disclosures from five major pharmaceutical companies, linking the issue to executive pay.

This story also ran in Asberry Financial Services, Environment Guru, Cetusnews.com, Morningstar

 

30th March 2018

SEC Says Pharma Firms Can’t Bar Vote on Link Between Drug Costs, CEO Pay

Financial Times – Agenda Week

The Securities and Exchange Commission has rejected requests from five large U.S. drug manufacturers who asked that they be allowed to omit shareholder proposals calling on them to consider whether or not there is a connection between soaring drug prices and rising executive pay in the pharmaceutical industry, the Boston Business Journal reports.

 

Coverage of Resolutions on Executive Incentives Tied to Drug Pricing

18th Dec 2017

ICCR Investors Seek More Info on Pay Incentives, Long-term Risks

 Health Economics

 Investors with the Interfaith Center on Corporate Responsibility (ICCR) on Wednesday filed resolutions with five major pharmaceutical companies in a bid to receive more information on executive pay incentives, and how they impact long-term financial risks.

14th Dec 2017

Do pharma's executive pay plans push up drug prices? Investors want to know

Fierce Pharma

Pharma investors may favor price hikes if the tactic means sales, profits and stock prices climb. But wary members of the Interfaith Center on Corporate Responsibility see things differently, and they're pushing several top drugmakers to review whether their executive pay contributes to high drug prices.

 

14th Dec 2017

Investor group targets pharmaceutical company pay practices for next proxy season

Pensions and Investments

Members of the Interfaith Center on Corporate Responsibility filed shareholder proposals at five U.S. pharmaceutical companies requesting the companies report how rising public concern over drug pricing is integrated into their incentive compensation practices for senior executives, said a news release from the ICCR Wednesday.

 

12th Dec 2017

Big Pharma Is Urged to Report on Links Between Pricing and Pay

Bloomberg

Pharmaceutical companies should be required to regularly report whether there’s a link between drug-pricing strategies and executive-compensation plans, according to a shareholder group.

 

 

 

 

 

 

 

Sign Up for our eNewsletter

* indicates required